On June 8, 2022, Biogen announced it withdrew its request to approve the use of aducanumab as a treatment for the early stage of Alzheimer’s disease.
Biogen said Health Canada indicated the evidence presented by it would not be sufficient to grant the company authorization to market aducanumab as a treatment.
“This decision will disappoint many people who had experienced positive responses to trials of the treatment, as well as those who had watched with interest and supported its approval for use in Canada,” said a statement for the Alzheimer Society of Canada.
“The Alzheimer Society of Canada respects the decision made by Biogen and renews its call for additional funding for dementia research. Canada’s per capita funding commitments are far behind the funds allocated for cancer and heart disease and we rank well behind several of our G7 peers.
"This must change so that new breakthroughs can be developed, tested and approved to provide hope for people living with dementia.”
- Alzheimer Society of Canada statement